Vaxart Inc (VXRT)

$0.32 0.00 (N/A)
Market Cap 97.49M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 11,568,300
Avg Vol 5,416,006
Day's Range N/A - N/A
Shares Out 228.31M
Stochastic %K 7%
Beta 1.14
Analysts Strong Sell
Price Target $4.67

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Season...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 550 3500
Fax: 650 871 8580
Website: vaxart.com
Address:
310 Utah Avenue, Suite 150, South San Francisco, United States
Garza759ify_YF
Garza759ify_YF Jun. 25 at 6:05 PM
$VXRT We came here to earn enormous, colossal return on investment. VXRT board will not stand in our way.
0 · Reply
justFrog
justFrog Jun. 25 at 6:05 PM
$VXRT while management ponders how much more they can bloat their salaries, come check out this tiny OTC telehealth play. 😂
0 · Reply
Tlb123
Tlb123 Jun. 25 at 6:00 PM
$VXRT I found this sentence pretty interesting. I had no idea forward progress hinged on this contract modification. “This contract modification was a necessary step to unblinding and reporting the first set of data from our sentinel cohort and underscores our progress toward the completion and reporting of the full data set from this breakthrough study,” & I’m sure Lo never discussed this stuff with a few investors he enjoys talking to. +’s and minuses in the PR but I prefer it silence
0 · Reply
Garza759ify_YF
Garza759ify_YF Jun. 25 at 6:00 PM
$VXRT Kick VXRT board out or all our efforts were for nothing.
0 · Reply
TahoeandChief
TahoeandChief Jun. 25 at 5:53 PM
$VXRT what the choose to PR vs what they choose not is is ludicrous
0 · Reply
Tycho11261
Tycho11261 Jun. 25 at 5:52 PM
$VXRT FEEL the value😂 Our expert leadership is so good. Nobody could ever good like they do. Without them, we are so doomed.
1 · Reply
Player2021
Player2021 Jun. 25 at 5:37 PM
$VXRT IF VAXART MANAGEMENT IS REALLY SERIOUS ABOUT NEGOTIATING…..TAKE ANY FUTURE REQUESTS FOR AN RS OFF THE DARN TABLE!!!! ….PERIOD!!
3 · Reply
Elementary_Trader
Elementary_Trader Jun. 25 at 5:35 PM
$VXRT I’m only posting a piece of what I’ve been reading, but with today’s technology, it will take that long *if they want it to*. They have had access to plenty of data, as the clinical portion was only 3 months, with monitoring the other 9 mos. Even the typing and organization of the findings is done electronically now. MUCH different than even 5 years ago.
0 · Reply
Dave247
Dave247 Jun. 25 at 5:30 PM
$VXRT
1 · Reply
bigdipper1
bigdipper1 Jun. 25 at 5:24 PM
$VXRT Lo bankrupt the last company he was CEO at we need him off the board as well as fired as CEO
0 · Reply
Latest News on VXRT
No data available.
Garza759ify_YF
Garza759ify_YF Jun. 25 at 6:05 PM
$VXRT We came here to earn enormous, colossal return on investment. VXRT board will not stand in our way.
0 · Reply
justFrog
justFrog Jun. 25 at 6:05 PM
$VXRT while management ponders how much more they can bloat their salaries, come check out this tiny OTC telehealth play. 😂
0 · Reply
Tlb123
Tlb123 Jun. 25 at 6:00 PM
$VXRT I found this sentence pretty interesting. I had no idea forward progress hinged on this contract modification. “This contract modification was a necessary step to unblinding and reporting the first set of data from our sentinel cohort and underscores our progress toward the completion and reporting of the full data set from this breakthrough study,” & I’m sure Lo never discussed this stuff with a few investors he enjoys talking to. +’s and minuses in the PR but I prefer it silence
0 · Reply
Garza759ify_YF
Garza759ify_YF Jun. 25 at 6:00 PM
$VXRT Kick VXRT board out or all our efforts were for nothing.
0 · Reply
TahoeandChief
TahoeandChief Jun. 25 at 5:53 PM
$VXRT what the choose to PR vs what they choose not is is ludicrous
0 · Reply
Tycho11261
Tycho11261 Jun. 25 at 5:52 PM
$VXRT FEEL the value😂 Our expert leadership is so good. Nobody could ever good like they do. Without them, we are so doomed.
1 · Reply
Player2021
Player2021 Jun. 25 at 5:37 PM
$VXRT IF VAXART MANAGEMENT IS REALLY SERIOUS ABOUT NEGOTIATING…..TAKE ANY FUTURE REQUESTS FOR AN RS OFF THE DARN TABLE!!!! ….PERIOD!!
3 · Reply
Elementary_Trader
Elementary_Trader Jun. 25 at 5:35 PM
$VXRT I’m only posting a piece of what I’ve been reading, but with today’s technology, it will take that long *if they want it to*. They have had access to plenty of data, as the clinical portion was only 3 months, with monitoring the other 9 mos. Even the typing and organization of the findings is done electronically now. MUCH different than even 5 years ago.
0 · Reply
Dave247
Dave247 Jun. 25 at 5:30 PM
$VXRT
1 · Reply
bigdipper1
bigdipper1 Jun. 25 at 5:24 PM
$VXRT Lo bankrupt the last company he was CEO at we need him off the board as well as fired as CEO
0 · Reply
Srive
Srive Jun. 25 at 5:24 PM
$VXRT we can see some positive momentum only after the current management change period.
0 · Reply
Srive
Srive Jun. 25 at 5:23 PM
$VXRT Don’t expect any progress Or Positive momentum from the current BOD/Management.
0 · Reply
WEN_PLUTO_BONES
WEN_PLUTO_BONES Jun. 25 at 5:22 PM
$VXRT The moral of the story. Technology validation is on its way along with DATA we haven’t ever seen. One way or another there’s light 💡 at the end of the tunnel. Place your plinko chips on red or black. 😉
1 · Reply
YetAnotherInvestor
YetAnotherInvestor Jun. 25 at 5:17 PM
$VXRT It would be funny if not for sad, how far the messaging is off from what they think they conveyed vs what people heard from the PR - I'm sure they thought this was making the case for their white card campaign - yet the reactions of people are completely opposite....
0 · Reply
TimLimb
TimLimb Jun. 25 at 5:08 PM
$VXRT ~25% market cap funded with additional none dilutive capital from BARDA. Nothing to see here # SEC
0 · Reply
Spankeee
Spankeee Jun. 25 at 5:08 PM
$VXRT I want directors who communicate important company advancements clearly, meet deadlines, work hard to increase share price, and appreciate investor value. Thanks for coming to my TED Talk.
0 · Reply
Dilly_Due
Dilly_Due Jun. 25 at 5:06 PM
$VXRT How good was the data on the ebola animal challenge study? How long would it take to revive the program and warp speed it with a BP partner? Have any experts had the opportunity to re-dissect the ebola data in the current environment? @Tm2424 perhaps? :-) Just my humble opinion. Do your own DD.
1 · Reply
PatrickKane88
PatrickKane88 Jun. 25 at 4:55 PM
$VXRT The platform could be revived for Ebola if BARDA/CEPI funding emerged, especially for Bundibugyo, where no approved vaccine exists — but this is speculative and not currently underway.
1 · Reply
PatrickKane88
PatrickKane88 Jun. 25 at 4:54 PM
$VXRT in Vaxart’s pipeline as of 2026. Their platform could theoretically be adapted for Ebola strains like Bundibugyo, but no such program is listed or funded today.
0 · Reply
PatrickKane88
PatrickKane88 Jun. 25 at 4:53 PM
$VXRT Vaxart has worked on Ebola — specifically an oral tablet Ebola vaccine — but only in preclinical studies. Their 2014 program showed protective efficacy in animal challenge studies, but never advanced to human trials
1 · Reply
PatrickKane88
PatrickKane88 Jun. 25 at 4:51 PM
$VXRT U.S. Rep. Jackie Speier D-San Mateo, toured Vaxart Wednesday to see the company’s efforts to develop the oral Ebola vaccine. In 2012, Vaxart was working on a vaccine that showed improved signs of immunity in mice.
1 · Reply
PatrickKane88
PatrickKane88 Jun. 25 at 4:51 PM
$VXRT South San Francisco-based Vaxart recently announced it would revive development of an experimental vaccine it stopped in 2012 due to low interest. So far, no vaccines for Ebola have been approved by the U.S. Food and Drug Administration, or FDA. However, the most recent outbreak of Ebola in West Africa that started in March has companies like Vaxart jumping on the chance to help combat the disease. The 20-person biotechnology company that develops vaccine technology for the treatment of infectious diseases, located at 385 Oyster Point Blvd., is working on developing an oral Ebola vaccine. It recently reported that it will ask the FDA to begin early safety clinical trials in humans in early 2015. During this most recent epidemic, so far, about 5,000 people have died from Ebola. “It’s an enormous step forward to address the challenges on the ground in West Africa,” said Vaxart CEO Wouter Latour. “We’d love to get the necessary resources for full-on services.”
0 · Reply